GNL Gut and Liver
  1. Seong Hee Kang, Minjong Lee, Moon Young Kim, Jun Hyeok Lee, Baek Gyu Jun, Tae Suk Kim, Dae Hee Choi, Ki Tae Suk, Young Don Kim, Gab Jin Cheon, Dong Joon Kim, Soon Koo Baik. The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study. Hepatol Int 2021;15:424
    https://doi.org/10.1007/s12072-021-10160-3
  2. Hiroki Nishikawa, Hirayuki Enomoto, Shuhei Nishiguchi, Hiroko Iijima. Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis. IJMS 2020;21:5254
    https://doi.org/10.3390/ijms21155254
  3. Sonia Selicean, Cong Wang, Sergi Guixé-Muntet, Horia Stefanescu, Norifumi Kawada, Jordi Gracia-Sancho. Regression of portal hypertension: underlying mechanisms and therapeutic strategies. Hepatol Int 2021;15:36
    https://doi.org/10.1007/s12072-021-10135-4
  4. Sasan Sakiani, Theo Heller, Christopher Koh. Current and investigational drugs in early clinical development for portal hypertension. Front. Med. 2022;9
    https://doi.org/10.3389/fmed.2022.974182
  5. Francesco Santopaolo, Gaetano Coppola, Lucia Giuli, Antonio Gasbarrini, Francesca Romana Ponziani. Influence of Gut–Liver Axis on Portal Hypertension in Advanced Chronic Liver Disease: The Gut Microbiome as a New Protagonist in Therapeutic Management. Microbiology Research 2022;13:539
    https://doi.org/10.3390/microbiolres13030038
  6. Seong Hee Kang, Woo Kyoung Jeong, Soon Koo Baik, Seung Hwan Cha, Moon Young Kim. Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score. Journal of Cachexia, Sarcopenia and Muscle 2018;9:860
    https://doi.org/10.1002/jcsm.12333
  7. Robert Schierwagen, Sabine Klein, Frank Uschner, Jonel Trebicka. Novel Targets and Drug Development in Portal Hypertension. Curr Hepatology Rep 2019;18:187
    https://doi.org/10.1007/s11901-019-00462-4
  8. Raffaele Bruno, Calogero Cammà, Paolo Caraceni, Gennaro D'Amico, Ignazio Grattagliano, Vincenzo La Mura, Oliviero Riggio, Filippo Schepis, Marco Senzolo, Paolo Angeli, Roberto de Franchis. Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease 2021;53:1089
    https://doi.org/10.1016/j.dld.2021.06.021
  9. Annalisa Berzigotti. Advances and challenges in cirrhosis and portal hypertension. BMC Med 2017;15
    https://doi.org/10.1186/s12916-017-0966-6
  10. Yuly P. Mendoza, Susana G. Rodrigues, Jaime Bosch, Annalisa Berzigotti. Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and meta-analysis. Digestive and Liver Disease 2020;52:958
    https://doi.org/10.1016/j.dld.2020.06.048
  11. Susana G. Rodrigues, Yuly P. Mendoza, Jaime Bosch. Investigational drugs in early clinical development for portal hypertension. Expert Opinion on Investigational Drugs 2022;31:825
    https://doi.org/10.1080/13543784.2022.2095259
  12. Xin Zeng, Xia Sheng, Pei-Qin Wang, Hai-Guang Xin, Yi-Bin Guo, Yong Lin, Jia-Wei Zhong, Cheng-Zhi He, Jie Yin, Tao-Tao Liu, Wei-Juan Ma, Xiao Xiao, Pei-Mei Shi, Zong-Li Yuan, Ling Yang, Xiong Ma, Jian-Ming Xu, Xi-Zhong Shen, Chang-Qing Yang, Xuan Zhu, Nong-Hua Lv, Wei-Fen Xie. Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis. Hepatol Int 2021;15:155
    https://doi.org/10.1007/s12072-020-10117-y
  13. Keiji Yokoyama, Hiromi Fukuda, Ryo Yamauchi, Masashi Higashi, Takashi Miyayama, Tomotaka Higashi, Yotaro Uchida, Kumiko Shibata, Naoaki Tsuchiya, Atsushi Fukunaga, Kaoru Umeda, Kazuhide Takata, Takashi Tanaka, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai. Long-Term Effects of Rifaximin on Patients with Hepatic Encephalopathy: Its Possible Effects on the Improvement in the Blood Ammonia Concentration Levels, Hepatic Spare Ability and Refractory Ascites. Medicina 2022;58:1276
    https://doi.org/10.3390/medicina58091276
  14. Haonan Zhang, Jian Gao, George Vousden. Antibiotics and probiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and a meta-analysis. PLoS ONE 2022;17:e0273231
    https://doi.org/10.1371/journal.pone.0273231
  15. Gyorgy Baffy. Potential mechanisms linking gut microbiota and portal hypertension. Liver Int 2019;39:598
    https://doi.org/10.1111/liv.13986
  16. Dmitry Victorovich Garbuzenko, Nikolay Olegovich Arefyev. Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis: An update and review of the literature. J Evid Based Med. 2020;13:313
    https://doi.org/10.1111/jebm.12407
  17. Eric Kalo, Scott Read, Golo Ahlenstiel. Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. Livers 2021;1:147
    https://doi.org/10.3390/livers1030014
  18. Jun Kyoung, Rohit R. Atluri, Tao Yang. Resistance to Antihypertensive Drugs: Is Gut Microbiota the Missing Link?. Hypertension 2022;79:2138
    https://doi.org/10.1161/HYPERTENSIONAHA.122.19826
  19. Paolo Caraceni, Victor Vargas, Elsa Solà, Carlo Alessandria, Koos Wit, Jonel Trebicka, Paolo Angeli, Rajeshwar P. Mookerjee, François Durand, Elisa Pose, Aleksander Krag, Jasmohan S. Bajaj, Ulrich Beuers, Pere Ginès, Adrià Juanola, Laura Napoleone, Marta Carol, Emma Avitabile, Ann Ma Thu, Marta Cervera, Martina Pérez, Ana Belén Rubio‐Garcia, Alicia Ardiaca, Adriana Vives, Judit Pich, Núria Fabrellas, Giacomo Zaccherini, Maria Teresa Chiappa, César Jiménez, Ester Palacio, Daniela Campion, Tommaso Lanzillotti, Salvatore Piano, Gea Nicolao, Frank Uschner, Sabine Graf_Dirmeier, Claire Francoz, Olivier Roux, Vanessa Esnault, Jeltje Helder, Marites Aban, Konstantin Kazankov, Marko Korenjak, Patrick Kamath, Juan G. Abraldes, Hugh Watson. The Use of Rifaximin in Patients With Cirrhosis. Hepatology 2021;74:1660
    https://doi.org/10.1002/hep.31708
© 2023. Gut and Liver. / Powered by INFOrang Co., Ltd